FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135883125> ?p ?o ?g. }

• W3135883125 endingPage "854" @default.
• W3135883125 startingPage "839" @default.
• W3135883125 abstract "Fruquintinib is an oral vascular endothelial growth factor receptor inhibitor. Previous gefitinib studies with anti-angiogenics show promising efficacy. This phase II trial assessed efficacy and safety of fruquintinib in combination with gefitinib, in patients with advanced non-small cell lung cancer (NSCLC).Fifty patients with stage IIIB/IV NSCLC and an epidermal growth factor receptor (EGFR) exon-19 deletion or exon-21 L858R mutation were enrolled between January 2017 and June 2019. Per protocol (version 1.0), patients received 4 mg fruquintinib once daily (qd) Days 1-21 of Cycle 1, using a 3-week-on/1-week-off schedule, plus continuous gefitinib 250 mg qd. If tolerated, patients proceeded to fruquintinib 5 mg qd (fruquintinib 5 mg group, n=26). Following protocol updates, dose escalation of fruquintinib from 4 mg qd to 5 mg qd was not allowed. The primary efficacy endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), time to response, duration of response and adverse events (AEs).ORR was 73.5% (95% CI, 58.9-85.1) and DCR was 98.0% (95% CI, 89.2-100.0). Median PFS was 14.7 months for both groups; PFS was highest for patients with exon-19 deletion (16.5 months; 95% CI, 12.9-21.2). Grade ≥3 treatment-emergent AEs occurred in 17 (65.3%; fruquintinib 5 mg,) and 11 patients (45.8%; 4 mg). Serious AEs were recorded for nine patients (fruquintinib 5 mg, six patients; 4 mg, three).Fruquintinib and gefitinib treatment showed an acceptable safety profile and promising efficacy in patients with NSCLC." @default.
• W3135883125 created "2021-03-15" @default.
• W3135883125 creator A5004928583 @default.
• W3135883125 creator A5009863367 @default.
• W3135883125 creator A5017100408 @default.
• W3135883125 creator A5020140861 @default.
• W3135883125 creator A5046361989 @default.
• W3135883125 creator A5052132950 @default.
• W3135883125 creator A5072410864 @default.
• W3135883125 creator A5075996595 @default.
• W3135883125 creator A5079270826 @default.
• W3135883125 creator A5082399148 @default.
• W3135883125 creator A5088242164 @default.
• W3135883125 date "2021-02-01" @default.
• W3135883125 modified "2023-10-13" @default.
• W3135883125 title "Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study" @default.
• W3135883125 cites W1842992197 @default.
• W3135883125 cites W1987273031 @default.
• W3135883125 cites W2025652939 @default.
• W3135883125 cites W2049674541 @default.
• W3135883125 cites W2076178766 @default.
• W3135883125 cites W2088540000 @default.
• W3135883125 cites W2094771796 @default.
• W3135883125 cites W2114461323 @default.
• W3135883125 cites W2132157071 @default.
• W3135883125 cites W2133283856 @default.
• W3135883125 cites W2135140316 @default.
• W3135883125 cites W2135192471 @default.
• W3135883125 cites W2140980839 @default.
• W3135883125 cites W2145835533 @default.
• W3135883125 cites W2150335765 @default.
• W3135883125 cites W2159717588 @default.
• W3135883125 cites W2166573361 @default.
• W3135883125 cites W2170030318 @default.
• W3135883125 cites W2403503949 @default.
• W3135883125 cites W2416043078 @default.
• W3135883125 cites W2560717039 @default.
• W3135883125 cites W2607454228 @default.
• W3135883125 cites W2728166834 @default.
• W3135883125 cites W2769211198 @default.
• W3135883125 cites W2770828094 @default.
• W3135883125 cites W2783363324 @default.
• W3135883125 cites W2790508405 @default.
• W3135883125 cites W2791317604 @default.
• W3135883125 cites W2792692302 @default.
• W3135883125 cites W2889646458 @default.
• W3135883125 cites W2937223370 @default.
• W3135883125 cites W2943606118 @default.
• W3135883125 cites W2943846365 @default.
• W3135883125 cites W2968084880 @default.
• W3135883125 cites W2978677918 @default.
• W3135883125 cites W2999746919 @default.
• W3135883125 cites W3027696049 @default.
• W3135883125 cites W3035912193 @default.
• W3135883125 cites W3142643682 @default.
• W3135883125 doi "https://doi.org/10.21037/tlcr-20-1028" @default.
• W3135883125 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7947379" @default.
• W3135883125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33718026" @default.
• W3135883125 hasPublicationYear "2021" @default.
• W3135883125 type Work @default.
• W3135883125 sameAs 3135883125 @default.
• W3135883125 citedByCount "4" @default.
• W3135883125 countsByYear W31358831252022 @default.
• W3135883125 countsByYear W31358831252023 @default.
• W3135883125 crossrefType "journal-article" @default.
• W3135883125 hasAuthorship W3135883125A5004928583 @default.
• W3135883125 hasAuthorship W3135883125A5009863367 @default.
• W3135883125 hasAuthorship W3135883125A5017100408 @default.
• W3135883125 hasAuthorship W3135883125A5020140861 @default.
• W3135883125 hasAuthorship W3135883125A5046361989 @default.
• W3135883125 hasAuthorship W3135883125A5052132950 @default.
• W3135883125 hasAuthorship W3135883125A5072410864 @default.
• W3135883125 hasAuthorship W3135883125A5075996595 @default.
• W3135883125 hasAuthorship W3135883125A5079270826 @default.
• W3135883125 hasAuthorship W3135883125A5082399148 @default.
• W3135883125 hasAuthorship W3135883125A5088242164 @default.
• W3135883125 hasBestOaLocation W31358831251 @default.
• W3135883125 hasConcept C121608353 @default.
• W3135883125 hasConcept C126322002 @default.
• W3135883125 hasConcept C143998085 @default.
• W3135883125 hasConcept C197934379 @default.
• W3135883125 hasConcept C203092338 @default.
• W3135883125 hasConcept C2776256026 @default.
• W3135883125 hasConcept C2779438470 @default.
• W3135883125 hasConcept C2780580887 @default.
• W3135883125 hasConcept C31760486 @default.
• W3135883125 hasConcept C535046627 @default.
• W3135883125 hasConcept C71924100 @default.
• W3135883125 hasConcept C90924648 @default.
• W3135883125 hasConceptScore W3135883125C121608353 @default.
• W3135883125 hasConceptScore W3135883125C126322002 @default.
• W3135883125 hasConceptScore W3135883125C143998085 @default.
• W3135883125 hasConceptScore W3135883125C197934379 @default.
• W3135883125 hasConceptScore W3135883125C203092338 @default.
• W3135883125 hasConceptScore W3135883125C2776256026 @default.
• W3135883125 hasConceptScore W3135883125C2779438470 @default.
• W3135883125 hasConceptScore W3135883125C2780580887 @default.
• W3135883125 hasConceptScore W3135883125C31760486 @default.

• next